Ibtissam Marchiq

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.

Matthew J. Frigault, M. Mohty, R. Benjamin, 2022, The Lancet. Haematology.

Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?

P. Bousso, C. Buchholz, K. Reiche, 2022, Journal for ImmunoTherapy of Cancer.

Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H+ symporters

J. Pouysségur, I. Marchiq, Ibtissam Marchiq, 2015, Journal of Molecular Medicine.

Optimized Protocol for the In Situ Derivatization of Glutathione with N-Ethylmaleimide in Cultured Cells and the Simultaneous Determination of Glutathione/Glutathione Disulfide Ratio by HPLC-UV-QTOF-MS

P. Oefner, J. Pouysségur, Xueni Sun, 2020, Metabolites.

Disrupting the 'Warburg effect' re-routes cancer cells to OXPHOS offering a vulnerability point via 'ferroptosis'-induced cell death.

J. Pouysségur, M. Vucetic, I. Marchiq, 2017, Advances in biological regulation.

CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors

J. Pouysségur, S. Critchlow, D. Roux, 2011, Proceedings of the National Academy of Sciences.

Time to evolve: predicting engineered T cell-associated toxicity with next-generation models

M. Kersten, A. Galy, M. Renner, 2022, Journal for ImmunoTherapy of Cancer.

Hypoxia and cancer metabolism : genetic and functional analysis of H+/lactate symporters and their chaperone, BASIGIN

I. Marchiq, Ibtissam Marchiq, 2015 .